Moderna is being added to the S&P 500

This post was originally published on this site

Moderna, the biotech that became a household name with its Covid-19 vaccine, is getting the ultimate Wall Street validation: It’s being added to the S&P 500 index.

© Angela Weiss/AFP/Getty Images A vial of the Moderna Covid-19 vaccine and syringes sit prepared at a pop up vaccine clinic at the Jewish Community Center on April 16, 2021 in the Staten Island borough of New York City.

S&P made the announcement late Thursday, and shares of Moderna surged 7% Friday morning in premarket trading on the news. The stock is now up nearly 170% this year, giving Moderna a market valuation of more than $100 billion.

Load Error

Moderna’s addition to the S&P 500 means that the scores of passively managed mutual funds and exchange-traded funds that mirror the S&P 500 will need to add the company’s stock to their portfolios. That’s a key reason that the stock was popping Friday.

Moderna will take the place of drug maker Alexion Pharmaceuticals, which is in the process of being acquired by Big Pharma giant AstraZeneca.

S&P said the index change will take effect before the market opens next Wednesday.

Moderna makes one of the three coronavirus vaccines that is approved by the United States Food and Drug Administration. Pfizer and BioNTech also make a two-dose vaccine similar to Moderna’s, while Johnson & Johnson offers a single-dose Covid shot.

Continue Reading